Epigenetic Approaches to Diagnosis and Therapy of COVID-19: Features of Differential DNA Methylation Profile as Potential Targets for Therapy by the Method of RNA Interference

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

In this article the role of epigenetic factors, as DNA methylation, in the processes of interaction of the SARS-CoV-2 virus with the human body and in the pathogenesis of COVID-19 is being considered. An overview of experimental studies on the use of microRNA to regulate the expression of genes processed during the interaction of the virus with the host body is presented. A potential new strategy in the diagnosis and therapy of COVID-19 and other viral factors using RNA interference is considered.

Sobre autores

O. Belopolskaya

Vavilov Institute of General Genetics Russian Academy of Sciences

Email: olesya.belopolskaya@vigg.ru
Moscow, Russia

S. Borinskaya

Vavilov Institute of General Genetics Russian Academy of Sciences

Moscow, Russia

A. Rimskaya

Vavilov Institute of General Genetics Russian Academy of Sciences

Moscow, Russia

N. Markina

Vavilov Institute of General Genetics Russian Academy of Sciences

Moscow, Russia

N. Yankovsky

Vavilov Institute of General Genetics Russian Academy of Sciences

Moscow, Russia

Bibliografia

  1. coronavirus-graph.ru
  2. Lai C.C., Shih T.P., Ko W.C. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges // Int. J. Antimicrob. Agents. 2020. V. 5. № 3. https://doi.org/ 10.1016/j.ijantimicag.2020.105924
  3. Devarakonda C.K.V., Meredith E., Ghosh M., Shapiro L.H. Coronavirus receptors as immune modulators // J. Immunol. 2021. V. 206. № 3. P. 923–929. https://doi.org/10.4049/jimmunol.2001062
  4. Kumar A., Narayan R.K., Prasoon P. et al. COVID-19 mechanisms in the human body – what we know so far // Front. Immunol. 2021. V. 12. https://doi.org/10.3389/fimmu.2021.693938
  5. Thunders M., Delahunt B. Gene of the month: TMPRSS2 (transmembrane serine protease 2) // J. Clin. Pathol. 2020. V. 73. № 12. P. 773–776. https://doi.org/10.1136/jclinpath-2020-206987
  6. Lucas S. Where does SARS-CoV-2 go to in man? // J. Pathol. 2022. V. 258. № 3. P. 211–212. https://doi.org/10.1002/path.6003
  7. Liu J., Li Y., Liu Q. et al. SARS-CoV-2 cell tropism and multiorgan infection // Cell Discov. 2021. V. 7. № 1. P. 17. https://doi.org/10.1038/s41421-021-00249-2
  8. Mehta P., McAuley D.F., Brown M.S. et al. COVID-19: Consider cytokine storm syndromes and immunosup-pression // Lancet. 2020. V. 395. № 10229.P. 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
  9. Saksena N., Bonam S.R., Miranda-Saksena M. Еpigenetic lens to visualize the severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection in covid-19 pandemic // Frontiers in Genetics. 2021. V. 12. https://doi.org/10.3389/fgene.2021.581726
  10. Masood K.I., Yameen M., Ashraf J. et al. Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome // Sci. Rep. 2021. V. 11. № 1. P. 22958. https://doi.org/10.1038/s41598-021-02489-4
  11. Khan A., Sergi C. SAMHD1 as the potential link between SARS-CoV-2 infection and neurological complications // Front. Neurol. 2020. V. 11. https://doi.org/10.3389/fneur.2020.562913
  12. Wang X., Xia H., Liu S. et al. Epigenetic regulation in antiviral innate immunity // Eur. J. Immunol. 2021. V. 51. № 7. P. 1641–1651. https://doi.org/10.1002/eji.202048975
  13. Russo C., Morello G., Malaguarnera R. et al. Candidate genes of SARS-CoV-2 gender susceptibility // Sci. Rep. 2021. V. 11. № 1. P. 21968. https://doi.org/10.1038/s41598-021-01131-7
  14. Leite M.M., Gonzalez-Galarza F.F., Silva B. et al. Predictive immunogenetic markers in COVID-19 // Hum. Immunol. 2021. V. 82. № 4. P. 247–254. https://doi.org/10.1016/j.humimm.2021.01.008
  15. Marzano F., Guerrini L., Pesole G. et al. Emerging roles of TRIM8 in health and disease // Cells. 2021. V. 10. Р. 3. https://doi.org/10.3390/cells10030561
  16. Arman K., Dalloul Z., Bozgeyik E. Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics // Gene. 2023. V. 861. https://doi.org/10.1016/j.gene.2023.147232
  17. Calzari L., Zanotti L., Inglese E. et al. Role of epigenetics in the clinical evolution of COVID-19 disease. Epigenome-wide association study identifies markers of severe outcome // Eur. J. Med. Res. 2023. V. 28. № 1. P. 81. https://doi.org/ 10.1186/s40001-023-01032-7
  18. Nyati K.K., Kishimoto T. Recent advances in the role of arid5a in immune diseases and cancer // Front. Immunol. 2021. V. 12. https://doi.org/10.3389/fimmu.2021.827611
  19. Schulte-Schrepping J., Reusch N., Paclik D. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment // Cell. 2020. V. 182. № 6. P. 1419–1440. https://doi.org/10.1016/j.cell.2020.08.001
  20. Mardomi A., Mohammadi N., Khosroshahi H.T., Abediankenari S. An update on potentials and promises of T cell co-signaling molecules in transplantation // J. Cell. Physiol. 2020. V. 235. № 5. P. 4183–4197. https://doi.org/10.1002/jcp.29369
  21. Fricke-Galindo I., Falfan-Valencia R. Genetics insight for COVID-19 susceptibility and severity: A review // Front. Immunol. 2021. V. 12. https://doi.org/10.3389/fimmu.2021.622176
  22. Cao W., Birkenbach M., Chen S. Patterns of inflammatory cell infiltration and expression of STAT6 in the lungs of patients with COVID-19: An autopsy study // Appl. Immunohistochem. Mol. Morphol. 2022. V. 30. № 5. P. 350–357. https://doi.org/10.1097/PAI.0000000000001023
  23. Bartoszewski R., Dabrowski M., Jakiela B. et al. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs // Am. J. Physiol. Lung Cell. Mol. Physiol. 2020. V. 319. № 3. P. 444–455. https://doi.org/10.1152/ajplung.00252.2020
  24. Yang C.Y., Chen Y.H., Liu P.J. et al. The emerging role of miRNAs in the pathogenesis of COVID-19: Protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection // Int. J. Med. Sci. 2022. V. 19. № 8. P. 1340–1356. https://doi.org/10.7150/ijms.76168
  25. Balmeh N., Mahmoudi S., Mohammadi N., Karabedianhajiabadi A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors // Informatics. Med. Unlocked. 2020. V. 20. https://doi.org/10.1016/j.imu.2020.100407
  26. Nersisyan S., Shkurnikov M., Turchinovich A. et al. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2 // PLoS One. 2020. V. 15. № 7. https://doi.org/10.1371/journal.pone.0235987
  27. Смелая Т.В., Кузовлев А.Н., Мороз В.В. и др. Молекулярно-генетические маркеры нозокомиальной пневмонии и острого респираторного дистресс-синдрома // Общая реаниматология. 2015. T. 11. № 3. C. 24–38. https://doi.org/10.15360/1813-9779-2015-3-24-38
  28. Donyavi T., Bokharaei-Salim F., Baghi H.B. et al. Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC // Int. Immuno-pharmacol. 2021. V. 97. https://doi.org/10.1016/j.intimp.2021.107641
  29. Fayyad-Kazan M., Makki R., Skafi N. et al. Circulating miRNAs: Potential diagnostic role for coronavirus disease 2019 (COVID-19) // Infect. Genet. Evol. 2021. V. 94. https://doi.org/10.1016/j.meegid.2021.105020
  30. De Gonzalo-Calvo D., Benítez I.D., Pinilla L. et al. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients // Transl. Res. 2021. V. 21. P. 122–125. https://doi.org/10.1016/J.TRSL.2021.05.004
  31. Sabbatinelli J., Giuliani A., Matacchione G. et al. Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients // Mech. Ageing Dev. 2021. V. 193. https://doi.org/10.1016/j.mad.2020.111413
  32. Narożna M., Rubiś B. Anti-sars-cov-2 strategies and the potential role of miRNA in the assessment of covid-19 morbidity, recurrence, and therapy // Int. J. Mol. Sci. 2021. V. 22. № 16.https://doi.org/10.3390/ijms22168663
  33. Sardar R., Satish D., Gupta D. Identification of novel sars-cov-2 drug targets by host micrornas and transcription factors co-regulatory interaction network analysis // Front. Genet. 2020. V. 11. https://doi.org/10.3389/fgene.2020.571274
  34. Schäfer A., Baric R.S. Epigenetic landscape during coronavirus infection // Pathogens. 2017. V. 6. https://doi.org/10.3390/pathogens6010008
  35. Khan M.A.A.K., Sany M.R.U., Islam M.S., Islam A.B.M.M.K. Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19 // Front. Genet. 2020. V. 11. https://doi.org/10.3389/fgene.2020.00765
  36. Alfano M., Sidenius N., Blasi F., Poli G. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection // J. Leukoc. Biol. 2003. V. 74. № 5. P. 750–756. https://doi.org/10.1189/jlb.0403176
  37. Konno H., Yamamoto T., Yamazaki K. et al. TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA // PLoS One. 2009. V. 4. № 5. https://doi.org/10.1371/journal.pone.0005674
  38. Oldstone M.B., Teijaro J.R., Walsh K.B., Rosen H. Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection // Virology. 2013. V. 435. № 1. P. 92–101. https://doi.org/10.1016/j.virol.2012.09.039
  39. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways // Cell Immunol. 2015. V. 294. № 2. P. 63–79. https://doi.org/10.1016/j.cellimm.2015.01.018
  40. Antoniak S., Owens A.P. 3rd, Baunacke M. et al. PAR-1 contributes to the innate immune response during viral infection // J. Clin. Invest. 2013. V. 123. № 3. P. 1310–1322. https://doi.org/10.1172/JCI66125
  41. Eddowes L.A., Al-Hourani K., Ramamurthy N. et al. Antiviral activity of bone morphogenetic proteins and activins // Nat. Microbiol. 2019. V. 4. № 2. P. 339–351. https://doi.org/10.1038/s41564-018-0301-9
  42. Lee Y.R., Tsai H.P., Yeh C.S. et al. RNA Interference approach is a good strategy against SARS-CoV-2 // Viruses. 2022. V. 15. № 1. https://doi.org/10.3390/v15010100
  43. Saadat K.A.S.M. RNAi-mediated siRNA sequences to combat the COVID-19 pandemic with the inhibition of SARS-CoV2 // Gene reports. 2022. V. 26. https://doi.org/10.1016/j.genrep.2022.101512
  44. Fopase R., Panda C., Rajendran A.P. et al. Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery // Front. in Bioengineering and Biotechnol. 2023. V. 11. https://doi.org/10.3389/fbioe.2023.1112755
  45. Matarese A., Gambardella J., Sardu C., Santulli G. miR-98 regulates TMPRSS2 expression in human endothelial cells: Key implications for COVID-19 // Biomedicines. 2020. V. 8. № 11. https://doi.org/10.3390/biomedicines8110462
  46. Salimi-Jeda A., Abbassi S., Mousavizadeh A. et al. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies // Int. Immunopharmacol. 2021. V. 101. Pt. A. https://doi.org/10.1016/j.intimp.2021.108232
  47. Underwood P.C., Adler G.K. The renin angiotensin aldosterone system and insulin resistance in humans // Curr. Hypertens. Rep. 2013. V. 15. P. 59–70. https://doi.org/10.1007/s11906-012-0323-2
  48. Shukla A.K., Banerjee M. Angiotensin-converting-enzyme 2 and renin-angiotensin system inhibitors in COVID-19: An update // High Blood Press. Cardiovasc. Prev. 2021. V. 28. P. 129–139. https://doi.org/10.1007/s40292-021-00439-9
  49. Cao X., Song L.N., Yang J.K. ACE2 and energy metabolism: The connection between COVID-19 and chronic metabolic disorders // Clin. Sci. 2021. V. 135. P. 535–554. https://doi.org/10.1042/CS20200752
  50. Choudhary S., Sreenivasulu K., Mitra P. et al. Role of genetic variants and gene expression in the susceptibility and severity of COVID-19 // Ann. Lab. Med. 2020. V. 41. P. 129–138. https://doi.org/10.3343/alm.2021.41.2.129
  51. Xu X., Chen P., Wang J. et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission // Sci. China Life Sci. 2020. V. 63. № 3. P. 457–460. https://doi.org/10.1007/s11427-020-1637-5
  52. Zou X., Chen K., Zou J. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection // Front. Med. 2020. V. 14. № 2. P. 185–192. https://doi.org/10.1007/s11684-020-0754-0
  53. Rotondo J.C., Martini F., Maritati M. et al. SARS-CoV-2 infection: New molecular, phylogenetic, and pathogenetic insights. Efficacy of current vaccines and the potential risk of variants // Viruses. 2021. V. 13. № 9. https://doi.org/10.3390/v13091687
  54. Biesalski H.K. Vitamin D deficiency and co-morbidities in COVID-19 patients – а fatal relationship? // NFS J. 2020. V. 20. P. 10–21. https://doi.org/10.1016/j.nfs.2020.06.001
  55. Razdan K., Singh K., Singh D. Vitamin D levels and COVID-19 susceptibility: Is there any correlation? // Med. Drug Discov. 2020. V. 7. https://doi.org/10.1016/j.medidd.2020.100051
  56. Chen X., Kang Y., Luo J. et al. Next-generation sequencing reveals the progression of COVID-19 // Front. Cell Infect. Microbiol. 2021. V. 11. https://doi.org/10.3389/fcimb.2021.632490
  57. Li M.-Y., Li L., Zhang Y., Wang X.-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues // Infect. Dis. Poverty 2020. V. 9. № 1. P. 45. https://doi.org/10.1186/s40249-020-00662-x
  58. Mahmoud I.S., Jarrar Y.B., Alshaer W., Ismail S. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention // Biochimie. 2020. V. 175. P. 93–98. https://doi.org/10.1016/j.biochi.2020.05.012
  59. Rotondo J.C., Aquila G., Oton-Gonzalez L. et al. Methylation of SERPINA1 gene promoter may predict chronic obstructive pulmonary disease in patients affected by acute coronary syndrome // Clin. Epigenetics. 2021. V. 13. P. 79. https://doi.org/10.1186/s13148-021-01066-w
  60. Martini F., De Mattei M., Contini C., Tognon M.G. Potential use of alpha-1 anti-trypsin in the Covid-19 treatment // Front. Cell Dev. Biol. 2020. V. 23. https://doi.org/10.3389/fcell.2020.577528
  61. Baughn L.B., Sharma N., Elhaik E. et al. Targeting TMPRSS2 in SARS-CoV-2 infection // Mayo Clin. Proc. 2020. V. 95. P. 1989–1999. https://doi.org/10.1016/j.mayocp.2020.06.018
  62. Liu Q., Du J., Yu X. et al. miRNA-200c-3p is crucial in acute respiratory distress syndrome // Cell Discov. 2017. V. 3. P. 17021. https://doi.org/10.1038/celldisc.2017.21
  63. Bozgeyik I. Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2 // Meta Gene. 2021. V. 27. https://doi.org/10.1016/j.mgene.2020.100831
  64. Lu D., Chatterjee S., Xiao K. et al. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes // J. Mol. Cell. Cardiol. 2020. V. 148. P. 46–49. https://doi.org/10.1016/j.yjmcc.2020.08.017
  65. Guo J., Huang Z., Lin L., Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: Aviewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection // J. Am. Heart Assoc. 2020. V. 9. https://doi.org/10.1161/JAHA.120.016219
  66. Widiasta A., Sribudiani Y., Nugrahapraja H. et al. Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy // Noncoding RNA Res. 2020. V. 5. P. 153–166. https://doi.org/10.1016/j.ncrna.2020.09.001
  67. Zhang C., Wang J., Ma X. et al. ACE2-EPC-EXs protect ageing ECs against hypoxia/reoxygenation-induced injury through the miR-18a/Nox2/ROS pathway // J. Cell Mol. Med. 2018. V. 22. P. 1873–1882. https://doi.org/10.1111/jcmm.13471
  68. Rao S., Lau A., So H.C. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits // Diabetes Care. 2020. V. 43. № 7. P. 1416–1426. https://doi.org/10.2337/dc20-0643
  69. Radovic N., Nikolić Jakoba N., Petrović N. et al. MicroRNA-146a and microRNA-155 as novel crevi-cular fluid biomarkers for periodontitis in non-diabetic and type 2 diabetic patients // J. Clin. Periodontol. 2018. V. 45. № 6. P. 663–671. https://doi.org/10.1111/jcpe.12888
  70. Roganovic J.R. microRNA-146a and -155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARS-CoV-2 oral receptors genes // J. Periodontol. 2020. V. 92. № 7. P. 35–43. https://doi.org/10.1002/JPER.20-0623
  71. Badry A., Jaspers V.L.B., Waugh C.A. Environ-mental pollutants modulate RNA and DNA virus-activated miRNA-155 expression and innate immune system responses: Insights into new immunomodulative mechanisms // J. Immunotoxicol. 2020. V. 17. P. 86–93. https://doi.org/10.1080/1547691X.2020.1740838
  72. Wyler E., Mösbauer K., Franke V. et al. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy // Science. 2021. V. 24. № 3. https://doi.org/10.1016/j.isci.2021.102151
  73. Pierce J.B., Simion V., Icli B. et al. Computational analysis of targeting SARS-CoV-2, viral entry proteins ACE2 and tmprss2, and interferon genes by host microRNAs // Genes (Basel). 2020. V. 11. № 11. https://doi.org/10.3390/genes11111354
  74. Teodori L., Sestili P., Madiai V. et al. MicroRNAs bioinformatics analyses identifying HDAC pathway as a putative target for existing anti-COVID-19 therapeutics // Front. Pharmacol. 2020. V. 11. https://doi.org/10.3389/fphar.2020.582003
  75. Calderon-Dominguez M., Trejo-Gutierrez E., González-Rovira A. et al. Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients // Mol. Ther. Nucleic Acids. 2022. V. 29. P. 76–87. https://doi.org/10.1016/j.omtn.2022.06.006
  76. Giovannoni F., Quintana F.J. SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic tar-get // Cell Res. 2021. V. 31. P. 1–2. https://doi.org/10.1038/s41422-020-00447-9
  77. Giovannoni F., Bosch I., Polonio C.M. et al. AHR is a zika virus host factor and a candidate target for antiviral therapy // Nat. Neurosci. 2020. V. 23. P. 939–951. https://doi.org/10.1038/s41593-020-0664-0
  78. Andrade A.F., Borges K.S., Castro-Gamero A.M. et al. Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells // Anticancer Drugs. 2014. V. 25. № 1. P. 72–81. https://doi.org/10.1097/CAD.0000000000000028
  79. Lv J., Yu P., Wang Z. et al. ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques // Cell Mol. Immunol. 2021. V. 18. № 5. P. 1308–1310. https://doi.org/10.1038/s41423-021-00672-1
  80. Zhong W., Li B., Xu Y. et al. Hypermethylation of the micro-RNA 145 promoter is the key regulator for NLRP3 inflammasome-induced activation and plaque formation // JACC Basic Transl. Sci. 2018. V. 3. № 5. P. 604–624. https://doi.org/10.1016/j.jacbts.2018.06.004.
  81. Huai W., Zhao R., Song H. et al. Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription // Nat. Commun. 2014. V. 5. https://doi.org/10.1038/ncomms5738
  82. Castro de Moura M., Davalos V., Planas-Serra L. et al. Epigenome-wide association study of COVID-19 severity with respiratory failure // EBioMedicine. 2021. V. 66. https://doi.org/10.1016/j.ebiom.2021.103339
  83. Sagulenko V., Thygesen S.J., Sester D.P. et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC // Cell Death Differ. 2013. V. 20. № 9. P. 1149–1160. https://doi.org/10.1038/cdd.2013.37
  84. Xia S., Zhang Z., Magupalli V.G., Pablo J.L. et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1 // Nature. 2021. V. 593. № 7860. P. 607–611. https://doi.org/10.1038/s41586-021-03478-3
  85. Ediz C., Tavukcu H.H., Akan S. et al. Is there any association of COVID-19 with testicular pain and epididymo-orchitis? // Int. J. Clin. Pract. 2021. V. 75. № 3. https://doi.org/10.1111/ijcp.13753
  86. Kgatle M.M., Lawal I.O., Mashabela G. et al. COVID-19 is a multi-organ aggressor: Epigenetic and clinical marks // Frontiers in Immunology. 2021. V. 12. https://doi.org/10.3389/fimmu.2021.752380
  87. Dai L., Zhang G., Cheng Z. et al. Knockdown of LncRNA MALAT1 contributes to the suppression of inflammatory responses by up-regulating miR-146a in LPS-induced acute lung injury // Connect Tissue Res. 2018. V. 59. № 6. P. 581–592. https://doi.org/10.1080/03008207.2018.1439480
  88. Carvelli J., Demaria O., Vély F. et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis // Nature. 2020. V. 588. P. 146–150. https://doi.org/10.1038/s41586-020-2600-6
  89. Totura A.L., Baric R.S. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon // Curr. Opin. Virol. 2012. V. 2. № 3. P. 264–275. https://doi.org/10.1016/j.coviro.2012.04.004
  90. Bouayad A. Innate immune evasion by SARS-CoV-2: Сomparison with SARS-CoV // Rev. Med. Virol. 2020. V. 30. № 6. P. 1–9. https://doi.org/10.1002/rmv.2135
  91. Cuevas A.M., Clark J.M., Potter J.J. Increased TLR/MyD88 signaling in patients with obesity: Is there a link to COVID-19 disease severity? // Int. J. Obes. 2021. V. 45. № 5. P. 1152–1154. https://doi.org/10.1038/s41366-021-00768-8
  92. Da Silva S.J.R., do Nascimento J.C.F., Germano Mendes R.P. et al. Two years into the COVID-19 pandemic: Lessons learned // ACS Infect. Dis. 2022. V. 8. № 9. P. 1758–1814. https://doi.org/10.1021/acsinfecdis.2c00204
  93. Uludağ H., Parent K., Aliabadi H.M., Haddadi A. Prospects for RNAi therapy of COVID-19 // Front. Bioeng. Biotechnol. 2020. V. 8. https://doi.org/10.3389/fbioe.2020.00916
  94. Ferreira-Gomes M., Kruglov A., Durek P. et al. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself // Nat. Commun. 2021. V. 12. № 1. P. 1961. https://doi.org/10.1038/s41467-021-22210-3
  95. Lechowicz K., Drożdżal S., Machaj F. et al. COVID-19: Тhe potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection // J. Clin. Med. 2020. V. 9. № 6. https://doi.org/10.3390/jcm9061917
  96. Mousavi S.R., Sajjadi M.S., Khosravian F. et al. Dysregulation of RNA interference components in COVID-19 patients // BMC Res. Notes. 2021. V. 14. № 1. P. 401. https://doi.org/10.1186/s13104-021-05816-0

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Russian Academy of Sciences, 2025

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».